<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244283</url>
  </required_header>
  <id_info>
    <org_study_id>gjnh/mccormick/01</org_study_id>
    <secondary_id>EUDRACT no. 2005-004398-76</secondary_id>
    <nct_id>NCT00244283</nct_id>
  </id_info>
  <brief_title>A Comparison of Two Anaesthetic Methods of Protecting Heart Tissue During Cardiac Surgery</brief_title>
  <official_title>A Comparison of Myocardial Protection Using Preconditioning With Sevoflurane Against High Thoracic Epidural Analgesia for CABG Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Jubilee National Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society for Intravenous Anaesthesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Golden Jubilee National Hospital</source>
  <brief_summary>
    <textblock>
      To compare two different methods of protecting heart muscle from damage caused by a decreased&#xD;
      blood supply. Exposure to the anaesthetic agent sevoflurane can allow the heart muscle to&#xD;
      resist longer periods of low blood or oxygen supply without sustaining the amount of damage&#xD;
      that it would otherwise expect to. The use of thoracic epidural analgesia improves the blood&#xD;
      flow to the heart muscle and has also been shown to reduce the amount of damage the heart&#xD;
      muscle may otherwise sustain. The aim of this study is to compare these two methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery bypass grafting (CABG) is a common procedure performed to improve blood flow&#xD;
      to the heart in patients with severe ischaemic heart disease. Commonly, the heart has to be&#xD;
      stopped to allow this procedure to be performed and this is often achieved with cooling the&#xD;
      heart and perfusing it with a solution that stops the activity of the heart muscle. These&#xD;
      techniques stop the heart from beating which allows the surgery to be performed and also&#xD;
      reduce the oxygen requirements of the heart. This in turn reduces the damage the heart&#xD;
      suffers from the reduced blood flow to it which occurs while the arteries are being operated&#xD;
      on. Unfortunately, however, these techniques do not completely eliminate the risk of heart&#xD;
      muscle damage and so new methods of further reducing damage to the heart are continually&#xD;
      being investigated. Two methods relating to the anaesthetic techniques used have recently&#xD;
      been identified as potentially of benefit in this regard - the use of volatile anaesthetic&#xD;
      agents and the use of high thoracic epidural analgesia.&#xD;
&#xD;
      Volatile anaesthetic agents have been extensively investigated in the past few years with&#xD;
      regard to their apparent ability to mimic ischaemic preconditioning. Ischaemic&#xD;
      preconditioning refers to the phenomenon that if heart tissue is exposed to frequent, short&#xD;
      episodes of reduced blood or oxygen supply, followed by a longer spell, the heart is likely&#xD;
      to suffer a smaller area of damage than if it had never been exposed to the brief ischaemic&#xD;
      spells. This can be related clinically to the observation that patients with angina, who&#xD;
      subsequently suffer a heart attack, have a better prognosis than those patients who suffer a&#xD;
      heart attack without ever experiencing angina prior to the event. There have been numerous&#xD;
      studies demonstrating that the volatile anaesthetic agents (isoflurane, sevoflurane,&#xD;
      desflurane) appear to mimic this phenomenon, both in animal and human models. Numerous&#xD;
      studies have demonstrated favourable postoperative blood concentrations of cardiac troponin I&#xD;
      (a sensitive marker of heart damage), CK-MB (another marker of heart damage), atrial and&#xD;
      brain natriueretic peptides (markers of heart function) compared to those who did not receive&#xD;
      preconditioning. It has therefore been suggested that this may improve outcome following&#xD;
      cardiac surgery.&#xD;
&#xD;
      High thoracic epidural analgesia (HTEA) has also been shown to be beneficial following&#xD;
      cardiac surgery. This involves placing a small catheter near the nerves as they leave the&#xD;
      spinal cord. Local anaesthetic ccan be administered down this catheter to numb the areas of&#xD;
      the body supplied by these nerves. This provides very good pain relief and is widely used in&#xD;
      our hospital for this operation. It has been shown to be associated with a shorter time of&#xD;
      required artificial ventilation compared to standard pain relief with drugs such as morphine.&#xD;
      It has also been suggested that it may influence outcome with improved heart function&#xD;
      following the operation compared to those without HTEA. It appears to do this by improving&#xD;
      the blood flow to the heart. It has also been associated with a lower postoperative&#xD;
      concentration of cardiac troponin , CK-MB, atrial and brain natriuretic peptides. There has&#xD;
      not been any direct comparison of the two techniques, however, to assess if one is superior&#xD;
      to the other, or if the benefits of the two techniques are additive.&#xD;
&#xD;
      Comparison:&#xD;
&#xD;
      This study aims to assess if one technique confers more benefit than the other and if the&#xD;
      benefits are additive. This is important as many centres do not use thoracic epidural&#xD;
      analgesia for cardiac surgery and not all clinicians currently use volatile anaesthetics for&#xD;
      cardiac surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date>January 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of NT-proBNP as a biochemical marker of ventricular dysfunction</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma measurements of cardiac troponin I and CK-MB from baseline over the first two poatoperative days.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac morbidity/ mortality as defined by incidence of death, inotrope requirements, arrhythmias, left ventricular dysfunction, pulmonary oedema or myocardial infarction</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Coronary Artery Bypass Surgery</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High thoracic epidural analgesia</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting for elective CABG operations, with &gt;40 % left ventricular ejection&#xD;
             fraction, aged 40-80.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients at risk of epidural haematomas (i.e. platelets &lt;100, coagulopathies, on&#xD;
             anticoagulant therapies, INR&gt;1.4) or unsuited to HTEA (patient refusal, spinal&#xD;
             deformities).&#xD;
&#xD;
        Patients on drugs shown to manipulate the preconditioning phenomenon will also be excluded.&#xD;
        This includes those on diazoxide, nicorandil, oral sulfonylureas and theophyllines.&#xD;
&#xD;
        Patients with preoperative ECG morphologies likely to make interpretation difficult or&#xD;
        impossible including: left bundle branch block, cardiac pacemaker dependence.&#xD;
&#xD;
        Haemodynamically compromised patients requiring inotropic or balloon pump support&#xD;
        preoperatively.&#xD;
&#xD;
        Significant valvular disease. Preoperative elevated levels of troponin I or CKMB. Unstable&#xD;
        angina or angina in 24 hours preop&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schraag, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Golden Jubilee National Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin F McCormick, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Golden Jubilee National Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin F McCormick, MB ChB</last_name>
    <phone>44 141 951 5600</phone>
    <email>Martin.McCormick@gjnh.scot.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Schraag, MD PhD</last_name>
    <phone>44 141 951 5609</phone>
    <email>Stefan.Schraag@gjnh.scot.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Martin F McCormick, MB ChB</last_name>
      <phone>44 141 951 5600</phone>
      <email>Martin.McCormick@gjnh.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Schraag, MD PhD</last_name>
      <phone>44 141 951 5609</phone>
      <email>Stefan.Schraag@gjnh.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Martin F McCormick, MB ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorg Prinzlin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, Zaugg M. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology. 2003 Jun;98(6):1315-27.</citation>
    <PMID>12766638</PMID>
  </reference>
  <reference>
    <citation>Berendes E, Schmidt C, Van Aken H, Hartlage MG, Wirtz S, Reinecke H, Rothenburger M, Scheld HH, Schl√ºter B, Brodner G, Walter M. Reversible cardiac sympathectomy by high thoracic epidural anesthesia improves regional left ventricular function in patients undergoing coronary artery bypass grafting: a randomized trial. Arch Surg. 2003 Dec;138(12):1283-90; discussion 1291.</citation>
    <PMID>14662525</PMID>
  </reference>
  <verification_date>October 2005</verification_date>
  <study_first_submitted>October 24, 2005</study_first_submitted>
  <study_first_submitted_qc>October 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2005</study_first_posted>
  <last_update_submitted>October 24, 2005</last_update_submitted>
  <last_update_submitted_qc>October 24, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2005</last_update_posted>
  <keyword>Myocardial preconditioning</keyword>
  <keyword>anesthetics</keyword>
  <keyword>epidural anesthesia</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>NT proBNP</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

